Fri, Nov 28, 2014, 12:05 PM EST - U.S. Markets close early today in 55 mins. for The day after Thanksgiving

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Reply to Red deleted post

    by koolbrez22 Oct 12, 2014 1:03 AM

    Could you be more specific about what Siegall or the company spokespeople said that you find to be damaging? I've read the press release, which seemed reasonably accurate but did not hear the conference call. Based on the study description in clinicaltrials.gov, the trial has proceeded as planned and successfully achieved its primary goal of testing for an effect on DFS. The assessment of OS is a secondary outcome and not scheduled to be reported until April 2016, and as already noted, the OS results are supposed to remain blinded until that time. So, did the SGEN people fail to make clear that, as expected, there were no results that could be reported on OS at this time?

    What puzzles me, however, is why so much weight is put on this trial. It was limited to patients who had not previously received Adcetris, and isn't the company pushing hard to get the agent approved for frontline therapy? If the effort succeeds, the Aethera trial result may apply to even fewer patients in future than it does now.

  • Reply to

    Reply to Red deleted post

    by koolbrez22 Oct 12, 2014 1:03 AM

    He is under the hay stack, fast asleep.

  • Reply to

    Reply to Red deleted post

    by koolbrez22 Oct 12, 2014 1:03 AM

    Hey Red and Kool. Disagree with Red. Kool makes sense. Watch BB. Almost that simple. Downtrend is typical herd mentality reaction I believe. SGEN always does what is right for patients and SGEN. Never caters to stock traders and hope it never does. If their science continues to show these great results- stockholders will be ver happy. Anyone know what happened to Ricarduno the SGEN bull?

    Sentiment: Buy

  • Reply to

    Reply to Red deleted post

    by koolbrez22 Oct 12, 2014 1:03 AM

    If anyone is wondering what this is about: A few days ago, I wrote a conjectural post inviting a debate over whether Clay Siegall should be invited to stay as SGEN's chief science officer but ousted as CEO on the basis of his serial failures to communicate effectively with Wall Street and the media, failures that repeatedly damage investors. I deleted the post to fix a typo, but Yahoo's top-notch system wouldn't let me re-post it.

    The argument for: Some people are very good at one thing, and rather bad at another. Siegall and his hapless media/investor relations advisers do not learn from previous mistakes in the public arena and, instead, keep repeating them. (Inviting positive speculation over the weekend about AETHERA results, then conducting a disastrous, unnecessarily evasive conference call when not mentally sharp at 5 a.m. local time Monday was just the latest example.)

    The argument against: Siegall's stellar success thus far in building the company. (Though, if these blunders continue, that success could be destroyed. I've seen other promising companies destroyed by public relations mistakes so egregious that they undermine the worth of the company and ultimately torpedo it.)

    I'm not necessarily advocating his ouster as CEO, just looking for a discussion of the issue and exactly the kind of response that Kool provided.

  • Reply to

    Reply to Red deleted post

    by koolbrez22 Oct 12, 2014 1:03 AM

    3) Results of ECHELON1 (the real biggie) should be imminent and common sense logic says that they should be confirming that which by now should be obvious (i.e. CRs are in excess of what already are excellent results with current SOP). WS spin will probably again hinge on OS not being established because it requires at least 5 years to be established, so it takes as long to expose their lies) but after the FDA expands the label and revenues go exponential, facts talk and BS walks.
    4) BBs, with a seat on the board have a bird's eye view of the real facts on the ground (as opposed to WS spin on speculation) were buyers of at least 2 million additional shares between $34 and $ 42 during the earlier Yellen induced dive. Therefore, unless they file a SEC document for a sale soon, things are progressing to expectations or better.
    So, again with all due respect to you Red, I'd rather keep Clay in charge than bring in someone new whose only qualifications to run a high tech company may be that he/she show super white capped fake pearlies when smiling.
    I'd join you kicking his #$%$ to nudge him into getting a PR crew deserving of the title that actually give a damn about doing a decent job of giving SGEN face and exposure.

  • Red,
    With all due respect for you (and I do have a lot of it for you), you are jumping the gun. Clay is as human as anyone else that could be hired to replace him. He is a CEO (i.e. a trained professional liar) and relatively speaking, he has done a good job. That does not mean that he is immune to screwing up from time to time (he did so royally last January/February in Lugano) but I don't see how anyone could anticipate and dispel Aethera results distortions such as " since Adcetris can induce a response even after a relapse, the FDA will not approve its use upfront because it is so good that it can remedy a relapse after it happens".
    We are talking about the big C here not cases of diarrhea (verbal in this case) so who cares about a few relapses among friends when there is a drug out there that can take care of it after the fact.
    After thinking about it objectively, is there really a chance in hell that the FDA would deny approval based on that kind of reasoning and putting it in print?
    How long would it be before a slew of congressmen prodded by their constituents would be irritating the FDA butt like a wet diaper?
    We all know the answer for that even those proposing it, however they also know that there is plenty of time from now to the FDA eventual ruling to shake a few shares lose and being in the midst of a market correction provides icing on the cake.
    Recent data shows that short float has decreased by ~ 2 million shares (from 17+ millions to 15 + millions as of 9/30, so it seems that some people have been taking full advantage of Clay's lapse of tongue.
    The facts on the ground remain that :
    1) Adcetris is confirmed to be highly effective in all of the uses where it has been expected to be so.
    2) Dozens of biotech companies (including several BPs) have endorsed SGEN AB technology and bet their money on it in several ongoing trial that, if successful, will result in over $ 4 billion in milestone payments plus significant ongoing royalties to SGEN.
    continue

  • Reply to

    Take a look

    by fstout57 Oct 11, 2014 11:19 AM

    Here's the latest new bio scam (IPO) claiming yet another cancer drug. CALA-see Adage Capital Partners and watch closely. Soon a rumor will get started on a possible buyout. Everyone will jump on board and they will make a ton. Then another start up investment and REPEAT. These hedge funds are running the portfolios of the 1%. Does anyone see a pattern here?

  • at RA Capital's selling in the last two weeks of ACHN. The same story on several other boards in the bio sector. If this was going to be a hot sector, they would be buying at these basement prices. Does not look good.

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    Jim Cramer has said many times that his opinions and The Streets opinions are two separate things. He works for The Street, but he is not The Street.

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    Rickarooster comes out whenever there is a downturn. He seems to feed off the falling price and spew out anything negative he can think of. I wouldn't be surprised if he had other aliases not mentioned. He may be a paid shill of the professional shorts. Perhaps his presence is an indicator of a bottoming in the market that is driving everything down...

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    He said it after the conference call. Also the Street articles say "we rate SGEN a sell". Look up what the Street has to say about SGEN in your search. I think I read it right below the news on the stock symbol once but verified it again in my search. You don't have to go by what they say. The negative EPS shows right on the stock so that means they are bleeding money. That number is supposed to be on the positive side.

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    I must have missed it and I follow Cramer quite a bit. When did he say sell? Where?

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    Yeah... he was dead wrong on this one.

  • Reply to

    All Bio's

    by fstout57 Oct 9, 2014 2:07 PM

    SILVER-Are you still out there? Did you buy HCP when I mentioned it on this board? Did anyone else? It may still go up but I sold today. Nice run-up when I posted interest rates were going to stay low. I suggested swapping out of SGEN and buying HCP with that great dividend and SILVER replied but haven't heard from you since.

  • Reply to

    The $29.00 price target

    by fstout57 Oct 9, 2014 12:21 PM

    Finally I am not being bashed and someone else thinks SGEN is not all that it was cracked up to be. I have not had anyone agree with me but now some are coming out of the woodwork. I just think there are plenty other stocks out there that aren't so deceiving as SGEN where the insiders are taking all the money from the company. Have I been wrong about any of my posts? This is still in a downward spiral hitting a 52 week low with more room to go. -

  • Reply to

    The $29.00 price target

    by fstout57 Oct 9, 2014 12:21 PM

    One thing I have learned in the Bio Techs is just buy the leaders like GILD, BIIB, AMGN, CELG and RGEN and let the spec plays go. I have lost a lot on SGEN and others but thinking they were long term plays. They always bite you in the #$%$

    Sentiment: Hold

  • Reply to

    The $29.00 price target

    by fstout57 Oct 9, 2014 12:21 PM

    No argument. Financial analysts also feel this way. Without an income stream they can't provide an accurate price projection.

    Sentiment: Hold

  • Reply to

    The $29.00 price target

    by fstout57 Oct 9, 2014 12:21 PM

    IMGN also has a negative EPS. Can't justify owning either of these until that number is positive.

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    You are so wrong. I don't know who those other people are but you seem to be long on this stock and losing so you say anyone posting negative remarks are the same person. Any response from Maui and fishman? How do we convince him we are not the same person?

  • Reply to

    Cramer's reversal

    by fstout57 Oct 9, 2014 1:50 PM

    All readers of this message board should know that fstout57, mauihope and fishman328 are the same troll - the one more widely known as rickarooski. This is a very sick individual who brings his various aliases to this board only when the stock falters, uses different 'voices' and approaches for each alias, and often engages in conversations with himself.

SGEN
36.845+0.055(+0.15%)12:05 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.